Genetic Signatures (ASX:GSS) EBIT : A$-19.28 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures EBIT?

Genetic Signatures's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was A$-12.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-19.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genetic Signatures's annualized ROC % for the quarter that ended in Dec. 2023 was -93.84%. Genetic Signatures's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -132.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Genetic Signatures's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -16.59%.

Genetic Signatures EBIT Historical Data

The historical data trend for Genetic Signatures's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures EBIT Chart

Genetic Signatures Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

-3.49

-2.05

1.79

3.08

-14.05

Genetic Signatures Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial													4.63	-1.55	-6.87	-7.18	-12.10

Competitive Comparison of Genetic Signatures's EBIT

For the Diagnostics & Research subindustry, Genetic Signatures's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Signatures's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's EV-to-EBIT falls into.

Genetic Signatures EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-19.28 Mil.

Genetic Signatures (ASX:GSS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genetic Signatures's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-24.202 * ( 1 - 0% )	/	( (27.926	+	23.658)	/ 2 )
=	-24.202	/	25.792
=	-93.84 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	49.078	-	4.803	-	( 16.349	-	max(0, 6.069	-	36.365	+	16.349	))
=	27.926

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	44.455	-	2.673	-	( 18.124	-	max(0, 3.83	-	30.875	+	18.124	))
=	23.658

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Genetic Signatures's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-24.202	/	( ( (7.224 + max(12.755, 0))	+	(7.582 + max(8.933, 0)) )	/	2 )
=	-24.202	/	( ( 19.979	+	16.515 )	/	2 )
=	-24.202	/	18.247
=	-132.64 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.194	+	8.753	+	6.877)	-	(4.803	+	0	+	1.266)
=	12.755

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.339	+	8.103	+	2.309)	-	(2.673	+	0	+	1.145)
=	8.933

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genetic Signatures's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-19.28	/	116.184
	=	-16.59 %

Genetic Signatures EBIT Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Signatures (ASX:GSS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042

Website

https://www.geneticsignatures.com

Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.